(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
27 December 2013 (27.12.2013)

WIPO | PCT

(10) International Publication Number
WO 2013/189901 A1

(51) **International Patent Classification**:
A61K 39/21 (2006.01) *C07K 14/005* (2006.01)

(21) **International Application Number**:
PCT/EP2013/062553

(22) **International Filing Date**:
17 June 2013 (17.06.2013)

(25) **Filing Language**: English

(26) **Publication Language**: English

(30) **Priority Data**:
61/661,050 18 June 2012 (18.06.2012) US

(71) **Applicant**: **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(72) **Inventors**: **CARFI, Andrea**; c/o Novartis Vaccines and Diagonstics, Inc., 4560 Horton Street, Emeryville, CA 94608-2916 (US). **DEY, Antu**; c/o Novartis Vaccines and Diagnostics, Inc., 4560 Horton Street, Emeryville, CA 94608-2916 (US). **KASSA, Aemro**; c/o Novartis Vaccines and Diagnostics, Inc., 4560 Horton Street, Emeryville, CA 94608-2916 (US). **SRIVASTAVA, Indresh**; c/o Novartis Vaccines and Diagnostics, Inc., 4560 Horton Street, Emeryville, CA 94608-2916 (US).

(74) **Agents**: **EVANS, Stephen, John, Eves** et al.; Novartis Vaccines and Diagnostics S.r.L., Via Fiorentina 1, I-53100 Siena (IT).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

— *with sequence listing part of description (Rule 5.2(a))*

WO 2013/189901 A1

(54) **Title**: STABILIZED GP120

(57) **Abstract**: The present invention provides an isolated polypeptide comprising an HIV gp120 polypeptideor soluble gp140 polypeptidestabilized in a conformation which exposes both CD4-bound and CD4- binding site epitopes. The invention also provides immunogenic compositions and methods of treating and preventing infection with HIV.